ß-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men
MetadataShow full item record
© 2016 American Association for Geriatric PsychiatryObjective To examine how ß-amyloid (Aß), APOE and BDNF genotypes, and cortisol relate to depressive and anxiety symptoms in cognitively normal older women and men. Methods Cross-sectional data were analyzed from 423 older adults from the Australian Imaging Biomarkers and Lifestyle study. Analyses of covariance evaluated associations between Aß, APOE and BDNF genotype, and cortisol in relation to severity of depressive and anxiety symptoms. Results Among Aß+ older adults, APOE e4 carriage was associated with greater severity of anxiety symptoms (d?=?0.55); and in the full sample, APOE e4 carriage was linked to greater severity of depressive (d?=?0.26) and anxiety (d?=?0.21) symptoms. Among Aß+ women, e4 carriers reported greater anxiety symptoms than non-e4 carriers (d?=?0.83), and female BDNF rs6265 Val66 Met allele carriers reported greater depressive symptoms (d?=?0.29). Conclusion Sex moderated the relationship between Aß, APOE genotype, and BDNF genotype in predicting severity of anxiety and depressive symptoms in cognitively normal older adults.
Showing items related by title, author, creator and subject.
Turner, Sian Elizabeth (2009)Background and research questions. The characterization of chronic persistent asthma in an older adult population is not well defined. This is due to the difficulties in separating the diagnosis of asthma from that of ...
Rees, Clare S. (1997)The overall aim of this project was to investigate the nature and structure of the physiological symptoms of panic attacks and the relationship between these symptoms and use of the health care system by people with a ...
Clarke, Patrick; Hicke, I.; Scott, E.; Guastella, A. (2012)Aim: Although the use of illness-staging models in clinical medicine has proved particularly useful, the concept has not been widely applied in mental health. Here, we apply a clinical staging framework to a population ...